Your Search for 'Hospira Generics Company Intelligence Report' returned 13 results - Page 1 of 1

• Generic Growth Strategies - Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs

  EURO€ 2,690.00USD$ 3,500.00GBP£ 2,263.00AUD$ 3,423.00JPY¥ 345,565.00SEK 22 980,00CHF 3'299.00CAD$ 3,566.00 GBI Research, Dec 2012 , Pages: 78
  strategies implemented by the top 10 generic companies in the generic drugs market along with company portfolios and strategic analysis. The report gives detail on the current landscape and changes that have ...

• The Pain Market Outlook to 2016

  EURO€ 2,948.00USD$ 3,835.00GBP£ 2,480.00AUD$ 3,751.00JPY¥ 378,641.00SEK 25 180,00CHF 3'615.00CAD$ 3,908.00 Scripp Business Insights, Jul 2011 , Pages: 155
  events, market trends, and issues. - Gain up-to-date competitive intelligence and understand the major issues affecting key pharmaceutical marketers and product development. - Forecast revenues for major ...

• The Pharmaceutical Market: USA

  EURO€ 985.00USD$ 1,281.00GBP£ 829.00AUD$ 1,253.00JPY¥ 126,522.00SEK 8 414,00CHF 1'208.00CAD$ 1,306.00 Espicom Business Intelligence Ltd, May 2012 , Pages: 178
  The Pharmaceutical Market: USA These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report ...

• Bone and Joint Infection Market to 2016 - Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment

  EURO€ 2,690.00USD$ 3,500.00GBP£ 2,263.00AUD$ 3,423.00JPY¥ 345,565.00SEK 22 980,00CHF 3'299.00CAD$ 3,566.00 GBI Research, Feb 2011 , Pages: 121
  7.2.7 Eli Lilly and Company 102 7.2.8 Pfizer Inc. 104 7.2.9 Hospira, Inc. 106 7.2.10 LEO Pharma A/S 107 7.2.11 APP Pharmaceuticals, Inc. 108 7.2.12 Abbott Laboratories 109 8 Bone and Joint Infection ...

• Global Biosimilars Industry

  EURO€ 653.00USD$ 850.00GBP£ 550.00AUD$ 831.00JPY¥ 83,923.00SEK 5 581,00CHF 801.00CAD$ 866.00 Taiyou Research, Oct 2012 , Pages: 315
  , Germany, India, Italy, Japan, Spain, the UK, and the US. - As we wrap up the report, we analyze the major players in the global biosimilars industry. All the players have been analyzed through a company ...

• Australia Pharmaceuticals and Healthcare Report Q2 2010

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Feb 2010 , Pages: 87
  the company’s desire to take advantage of the rising demand for generics. executive Summary SWOT Analysis - Australia Pharmaceuticals And Healthcare Industry SWOT - Australia Political SWOT ...

• Australia Pharmaceuticals and Healthcare Report Q2 2009

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Apr 2009 , Pages: 110
  Australia Pharmaceuticals and Healthcare Report Q2 2009 Australia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Australia's pharmaceuticals and ...

• Australia Pharmaceuticals and Healthcare Report Q4 2008

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Oct 2008 , Pages: 92
  Australia Pharmaceuticals and Healthcare Report Q4 2008 Australia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Australia's pharmaceuticals and ...

• Australia Pharmaceuticals and Healthcare Report Q3 2008

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Aug 2008 , Pages: 87
  Australia Pharmaceuticals and Healthcare Report Q3 2008 BMI's Australia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Australia's ...

• Australia Pharmaceuticals and Healthcare Report Q4 2009

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Aug 2009 , Pages: 98
  Australia Pharmaceuticals and Healthcare Report Q4 2009 The Australia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical ...

• Australia Pharmaceuticals and Healthcare Report Q1 2009

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Feb 2009 , Pages: 99
  Australia Pharmaceuticals and Healthcare Report Q1 2009 This Australia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Australia's pharmaceuticals ...

• Israel Pharmaceuticals and Healthcare Report Q1 2010

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Dec 2009 , Pages: 91
  company Hospira, as part of its strategy to reduce asset duplication. In news that is set to boost the export potential for Israeli companies, the European Union (EU) authorities recently announced that ...

• Australia Pharmaceuticals and Healthcare Report Q4 2010

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Aug 2010 , Pages: 96
  Australia Pharmaceuticals and Healthcare Report Q4 2010 Business Monitor International's Australia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate ...